![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Trevena Gets FDA Breakthrough Therapy Designation for Oliceridine
Trevena Gets FDA Breakthrough Therapy Designation for Oliceridine
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
February 26, 2016
King of Prussia, Pa.-based Trevena has scored a win at the FDA, with the agency granting it breakthrough therapy designation for intravenous oliceridine to manage moderate to severe acute pain.
Currently in Phase 3 development, oliceridine is eligible for FDA guidance on its development program — as well as rolling and priority review — as a result of the designation.
The FDA previously granted the candidate fast track designation.
Upcoming Events
-
21Oct